China’s first counter-sanction on US biotech industry marks a turning point in tech war
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Leading American genomic sequencing firm Illumina says it is evaluating Beijing’s announcement with hope of ‘positive resolution’.